
Next-Generation GLP-1 Therapies Advance as SureNano Develops Novel Triple Agonist Peptide
SureNano Science Ltd. is advancing a next-generation GLP-1 platform with its triple agonist peptide GEP-44, aiming to improve efficacy and delivery flexibility in the rapidly growing market for obesity and diabetes treatments.
Read full story























